Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#21 / 106 Total
ASNS - Actelis Networks Inc - Stock Price Chart
CompanyActelis Networks Inc
IndustryCommunication Equipment
Market Cap2.41MEPS (ttm)-4.62
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.32EPS next 5Y-
P/B1.88EPS Q/Q13.61%
Dividend-Sales Q/Q-38.46%
Insider Own15.32%Inst Own10.21%
Insider Trans-0.85%Inst Trans-59.44%
Short Float3.58%Earnings-
Analyst Recom-Target Price-
Avg Volume281.82K52W Range1.02 - 11.26
Actelis Networks, Inc. is a networking solutions company that implements communication for IoT projects. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create quick-to-deploy network. The firm develops broadband solutions for telecom service providers, enterprises and municipalities. It is accelerating broadband services to businesses and residential subscribers through Broadband Accelerator (BBA), EFMplus, Dynamic Rate Boost (DRB) and Dynamic Spectral Shaping (DSS). The company was founded by Yuval Baron, Tuvia Barlev and Kamran Elahian in 1997 and is headquartered in Fremont, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barlev TuviaCEO and Chairman of the BoardMay 17Sale3.322,1076,995163,598May 18 04:05 PM
Niv IsraelDirectorMay 17Sale3.324221,40167,218May 18 04:05 PM
PTN - Palatin Technologies Inc. - Stock Price Chart
TickerPTN [AMEX]
CompanyPalatin Technologies Inc.
Market Cap19.70MEPS (ttm)-2.53
P/E-EPS this Y30.04%
Forward P/E-EPS next Y72.88%
PEG-EPS past 5Y-
P/S4.06EPS next 5Y-
P/B148.70EPS Q/Q31.69%
Dividend-Sales Q/Q128.60%
Insider Own8.70%Inst Own7.63%
Insider Trans0.00%Inst Trans14.22%
Short Float4.19%EarningsSep 28/b
Analyst Recom1.00Target Price83.33
Avg Volume93.09K52W Range1.43 - 6.40
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUNTON ALAN WDirectorDec 21Sale2.9720059441,420Dec 23 05:30 PM
ELDN - Eledon Pharmaceuticals Inc - Stock Price Chart
CompanyEledon Pharmaceuticals Inc
Market Cap34.89MEPS (ttm)-6.12
P/E-EPS this Y68.91%
Forward P/E-EPS next Y25.77%
PEG-EPS past 5Y31.69%
P/S-EPS next 5Y-
P/B0.36EPS Q/Q38.44%
Dividend-Sales Q/Q-
Insider Own6.01%Inst Own42.08%
Insider Trans0.00%Inst Trans-2.38%
Short Float0.15%EarningsAug 10/b
Analyst Recom1.00Target Price14.80
Avg Volume64.94K52W Range1.08 - 3.70
Oct-02-23 07:00AM Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors (GlobeNewswire) +13.14%
Sep-25-23 07:00AM Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human (GlobeNewswire)
Sep-20-23 04:05PM Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 07:00AM Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-06-23 07:00AM Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates (GlobeNewswire) -11.89%
Sep-05-23 07:00AM Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
Aug-16-23 07:00AM Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation (GlobeNewswire)
Aug-10-23 07:00AM Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-12-23 07:30AM Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update (GlobeNewswire)
Jun-02-23 08:00AM Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference (GlobeNewswire)
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Perrin StevenPresidentNov 23Buy2.601,0002,5971,000Nov 23 04:05 PM
PTPI - Petros Pharmaceuticals Inc - Stock Price Chart
CompanyPetros Pharmaceuticals Inc
IndustryDrug Manufacturers - Specialty & Generic
Market Cap4.11MEPS (ttm)-10.58
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.07EPS next 5Y-
P/B0.32EPS Q/Q-37.30%
Dividend-Sales Q/Q-52.37%
Insider Own40.25%Inst Own4.83%
Insider Trans0.00%Inst Trans2.85%
Short Float0.30%Earnings-
Analyst Recom-Target Price-
Avg Volume360.14K52W Range0.92 - 9.54
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
FNGR - FingerMotion Inc - Stock Price Chart
CompanyFingerMotion Inc
IndustryTelecom Services
Market Cap363.93MEPS (ttm)-0.16
P/E-EPS this Y70.59%
Forward P/E233.33EPS next Y-
PEG-EPS past 5Y-2.69%
P/S8.80EPS next 5Y-
P/B26.04EPS Q/Q27.22%
Dividend-Sales Q/Q150.64%
Insider Own48.57%Inst Own1.29%
Insider Trans9.31%Inst Trans-7.08%
Short Float5.76%Earnings-
Analyst Recom1.00Target Price5.00
Avg Volume955.68K52W Range1.01 - 9.80
Fingermotion Inc. is a mobile data specialist company, which engages in the provision of payment and recharge service, data plans, subscription plans, mobile phones, loyalty points redemption, and other product bundles. It operates through the following segments: Telecommunications and Product Services, Value Added Products and Services, Short Message Services and Multimedia Messaging Services, Rich Communication Services Platform, and Big Data Insights. The company was founded on January 23, 2014, and is headquartered in Singapore.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shen Martin Chung-WenCEOSep 14Option Exercise3.8492,000353,280797,000Sep 14 06:42 PM
Lee Yew HonCFOSep 14Option Exercise3.8488,400339,456538,400Sep 14 06:28 PM
Leong Yew PohDirectorSep 05Sale5.7012,50071,250200,000Sep 05 07:28 PM
Leong Yew PohDirectorAug 30Sale5.502,17611,968212,500Aug 31 12:39 PM
Leong Yew PohDirectorJul 31Sale5.797,82445,319214,676Jul 31 07:27 PM
AXDX - Accelerate Diagnostics Inc - Stock Price Chart
CompanyAccelerate Diagnostics Inc
IndustryMedical Devices
Market Cap93.12MEPS (ttm)-8.01
P/E-EPS this Y6.84%
Forward P/E-EPS next Y54.97%
PEG-EPS past 5Y8.41%
P/S7.99EPS next 5Y30.00%
P/B-EPS Q/Q-22.37%
Dividend-Sales Q/Q-24.35%
Insider Own47.86%Inst Own15.60%
Insider Trans-0.87%Inst Trans-
Short Float4.71%EarningsAug 10/a
Analyst Recom2.00Target Price40.00
Avg Volume24.21K52W Range4.50 - 17.80
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patience DavidChief Financial OfficerSep 13Option Exercise0.0033108,324Sep 14 04:11 PM
Phillips JackChief Executive OfficerSep 13Option Exercise0.001,722057,322Sep 14 04:13 PM
Phillips JackChief Executive OfficerSep 13Sale6.537334,78656,589Sep 14 04:13 PM
Patience DavidChief Financial OfficerSep 13Sale6.53966278,228Sep 14 04:11 PM
Phillips JackChief Executive OfficerAug 14Sale6.807515,10755,600Aug 15 07:22 PM
NA - Nano Labs Ltd ADR - Stock Price Chart
TickerNA [NASD]
CompanyNano Labs Ltd ADR
Market Cap38.57MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B3.35EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.06%
Insider Trans-Inst Trans75.72%
Short Float-EarningsAug 15/b
Analyst Recom-Target Price-
Avg Volume80.31K52W Range0.92 - 2.97
Nano Labs Ltd. is a holding company, which engages in design and product solution provision of fabless integrated circuit. It offers high throughput computing chips, high performance computing chips, distributed computing and storage solutions, smart network interface cards, vision computing chips, and distributed rendering. The company was founded in July, 2019 and is headquartered in Hangzhou, China.
USIO - Usio Inc - Stock Price Chart
CompanyUsio Inc
IndustrySoftware - Infrastructure
Market Cap51.99MEPS (ttm)-0.09
P/E-EPS this Y-
Forward P/E18.47EPS next Y966.67%
PEG-EPS past 5Y4.00%
P/S0.67EPS next 5Y-
P/B3.45EPS Q/Q-
Dividend-Sales Q/Q31.12%
Insider Own42.46%Inst Own26.67%
Insider Trans0.00%Inst Trans-2.31%
Short Float0.45%EarningsAug 14/a
Analyst Recom1.50Target Price7.33
Avg Volume35.30K52W Range1.28 - 2.56
USIO, Inc. engages in providing integrated payment solutions. Its solutions include payment facilitation, merchant services, payment solutions, card issuing, check printing, electronic bill presentment & payment, and printing and mailing. The company offers services to software companies, merchants, billers, banks, service bureaus and card issuers. USIO was founded by Louis A. Hoch and Michael R. Long in July 1998 and is headquartered in San Antonio, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rollins BradDirectorApr 01Option Exercise1.7410,00017,400100,667Apr 04 12:45 PM
Bender BlaiseDirectorApr 01Option Exercise1.743,3335,79979,477Apr 04 12:53 PM
Frost Houston KorthSenior Vice PresidentFeb 08Option Exercise2.055001,025566,527Feb 22 11:11 AM
HOCH LOUIS AChairman, President and CEONov 18Option Exercise2.3510,00023,5002,694,591Nov 21 02:40 PM
Jewell Lowell ThomasSVP, CFONov 18Option Exercise2.357,00016,450562,222Nov 21 02:51 PM
EDUC - Educational Development Corp. - Stock Price Chart
CompanyEducational Development Corp.
Market Cap10.21MEPS (ttm)-0.43
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.13EPS next 5Y-
P/B0.23EPS Q/Q-
Dividend-Sales Q/Q-37.29%
Insider Own26.40%Inst Own24.48%
Insider Trans0.00%Inst Trans-0.44%
Short Float0.11%EarningsJul 13/a
Analyst Recom1.00Target Price8.50
Avg Volume24.82K52W Range1.00 - 4.00
Educational Development Corp. engages in the provision of educational children's books. It operates through the PaperPie and Publishing segments. The PaperPie segment sells books through independent consultants directly to customers by hosting home parties, through social media collaboration platforms on the internet, by hosting book fairs with school and public libraries. The Publishing segment sells its products to bookstores, toy stores, specialty stores, museums, and other retail outlets. The company was founded on August 23, 1965 and is headquartered in Tulsa, OK.
GPCR - Structure Therapeutics Inc ADR - Stock Price Chart
CompanyStructure Therapeutics Inc ADR
Market Cap2.03BEPS (ttm)-
P/E-EPS this Y83.62%
Forward P/E-EPS next Y-7.56%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B9.45EPS Q/Q-68.18%
Dividend-Sales Q/Q-
Insider Own2.73%Inst Own46.58%
Insider Trans0.00%Inst Trans-
Short Float6.58%EarningsAug 10/a
Analyst Recom1.00Target Price63.00
Avg Volume689.20K52W Range20.80 - 65.51
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.